Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
Enrique Grande, José Arranz, Maria De Santis, Aristotelis Bamias, Eiji Kikuchi, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Fabio A. Schutz, Javier Puente, Jian Ri Li, Peter H. O'Donnell, Arash Rezazadeh Kalebasty, Dingwei Ye, Sanjeev Mariathasan, Fabio Ia Bene-Tchaleu, Sandrine BernhardChooi Lee, Ian D. Davis, Matthew D. Galsky
Research output: Contribution to journal › Article › peer-review
21Scopus
citations
Fingerprint
Dive into the research topics of 'Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study'. Together they form a unique fingerprint.